Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)
China200 participantsStarted 2012-05
Plain-language summary
The purpose of this study is to confirm that Ulinastatin is a safe and effective drug and it can reduce the incidence of postoperative hepatic failure in HCC patients. To evaluate that Ulinastatin can improve survival in HCC patients or not.
Who can participate
Age range35 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female patients \> 35 years and \<=55 years of age.
✓. confirmed case (patients with HCC)
✓. Tumors can be radical removed and resection volume was 50% to 70%.
✓. Criteria of liver function: Child A level, serum bilirubin ≤ 1.5 times the upper limit of normal value,alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal value.
✓. No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung function are basically normal. Hbg ≥ 90g/L, WBC ≥ 3.000 cells/mm³,platelets ≥ 80.000 cells/mm³.
✓. Karnofsky Performance Score performance over 60.
✓. Patients who can understand this trial and have signed information consent.
Exclusion criteria
✕. Patients who have undergone previous treatment by Ulinastatin.
✕. Patients with apparent cardiac, pulmonary, cerebronic and renal dysfunction, which may affect the treatment of liver cancer.
✕. Patients with other diseases which may affect the treatment mentioned here.
✕. Patients with medical history of other malignant tumors.
✕. Subjects participating in other clinical trials.